CA3232002A1 - Nitric oxide releasing prostamide as neuroprotective agent - Google Patents
Nitric oxide releasing prostamide as neuroprotective agent Download PDFInfo
- Publication number
- CA3232002A1 CA3232002A1 CA3232002A CA3232002A CA3232002A1 CA 3232002 A1 CA3232002 A1 CA 3232002A1 CA 3232002 A CA3232002 A CA 3232002A CA 3232002 A CA3232002 A CA 3232002A CA 3232002 A1 CA3232002 A1 CA 3232002A1
- Authority
- CA
- Canada
- Prior art keywords
- hepten
- propen
- phenylethyl
- oxo
- ethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/075786 WO2023041182A1 (en) | 2021-09-20 | 2021-09-20 | Nitric oxide releasing prostamide as neuroprotective agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3232002A1 true CA3232002A1 (en) | 2023-03-23 |
Family
ID=77998957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3232002A Pending CA3232002A1 (en) | 2021-09-20 | 2021-09-20 | Nitric oxide releasing prostamide as neuroprotective agent |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240390390A1 (https=) |
| EP (1) | EP4404936A1 (https=) |
| JP (1) | JP2024533601A (https=) |
| CN (1) | CN117979973A (https=) |
| CA (1) | CA3232002A1 (https=) |
| TW (1) | TW202327617A (https=) |
| WO (1) | WO2023041182A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8147865B2 (en) * | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| AR076731A1 (es) | 2008-05-09 | 2011-07-06 | Pfizer | Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas |
| US11058691B2 (en) | 2016-11-08 | 2021-07-13 | Nicox S.A. | Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma |
| ES2923623T3 (es) | 2018-02-21 | 2022-09-29 | Nicox Sa | Procedimiento para la preparación de un análogo de prostaglandina donante de óxido nítrico |
| AU2019300203B2 (en) | 2018-07-12 | 2025-01-30 | Nicox S.A. | Ophthalmic compositions containing a nitric oxide releasing prostamide |
-
2021
- 2021-09-20 EP EP21782662.7A patent/EP4404936A1/en active Pending
- 2021-09-20 CN CN202180102507.6A patent/CN117979973A/zh active Pending
- 2021-09-20 JP JP2024517091A patent/JP2024533601A/ja active Pending
- 2021-09-20 WO PCT/EP2021/075786 patent/WO2023041182A1/en not_active Ceased
- 2021-09-20 US US18/693,676 patent/US20240390390A1/en active Pending
- 2021-09-20 CA CA3232002A patent/CA3232002A1/en active Pending
-
2022
- 2022-09-19 TW TW111135266A patent/TW202327617A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117979973A (zh) | 2024-05-03 |
| WO2023041182A1 (en) | 2023-03-23 |
| TW202327617A (zh) | 2023-07-16 |
| JP2024533601A (ja) | 2024-09-12 |
| US20240390390A1 (en) | 2024-11-28 |
| EP4404936A1 (en) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6242442B1 (en) | Brinzolamide and brimonidine for treating ocular conditions | |
| JP2011516537A (ja) | 安定性のある眼科用の製剤 | |
| US10213431B2 (en) | Preservative free brimonidine and timolol solutions | |
| US10292953B2 (en) | Pharmaceutical composition of ibuprofen and tramadol for ophthalmic use | |
| US20120277239A1 (en) | Compositions and Methods for Improving Night Vision | |
| KR20130052619A (ko) | 방부제가 없는 비마토프로스트 및 티몰롤 용액 | |
| JP2021046394A (ja) | ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物 | |
| US20150099807A1 (en) | Preservative free bimatoprost solutions | |
| ES2764654T3 (es) | Combinaciones de prostaglandinas y donantes de óxido nítrico | |
| US8178134B2 (en) | Synergistic herbal ophthalmic formulation for lowering intraocular pressure in case of glaucoma | |
| US20030007971A1 (en) | Remedies for ophthalmic diseases | |
| CA3232002A1 (en) | Nitric oxide releasing prostamide as neuroprotective agent | |
| HK40109915A (zh) | 作为神经保护剂的释放一氧化氮的前列腺酰胺 | |
| KR20230147006A (ko) | 무방부제 안과용 약학 에멀젼 및 이의 적용 | |
| Khan et al. | Beyond the local effect: an examination of cardiovascular and other systemic complications of ophthalmologic drugs | |
| EP4233867B1 (en) | Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy | |
| CA2398900A1 (en) | Therapeutic agents for opthalmopathy | |
| US20060172977A1 (en) | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage | |
| Sharpe et al. | A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost | |
| Garhofer | The Effect of Preservative Free Taf-luprost on Intraocular Pressure in Patients with Ocular Hypertension or Primary Open Angle Glaucoma | |
| Kanner et al. | Adrenergic Agents | |
| Lodhi et al. | Latanoprost 0.005% v/s timolol maleate 0.5% pressure lowering effect in primary open angle glaucoma | |
| Marc et al. | Ocular toxicity of topical indomethacin eye drops | |
| CN110496130A (zh) | 一种防治糖尿病性视网膜病变的药物组合物 | |
| Voskanyan et al. | BULLETIN OF STOMATOLOGY AND MAXILLO-FACIAL SURGERY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240903 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240903 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240903 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250812 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250812 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20250916 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250916 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250916 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251117 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20251117 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251117 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260205 |